Scalper1 News
Big-cap biotech Biogen Idec reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street’s expectations, but the stock rose just a fraction as biotechs had a bad day and Biogen revealed it’s being probed by authorities. Biogen (BIIB) said revenue rose 50.5% over the year-earlier quarter, to $2.13 billion, beating analysts’ consensus of $2 billion. But earnings per share of $2.47, up 25%, missed consensus of $2.56. The company, Scalper1 News
Scalper1 News